Genmab — Marts 2018
-
Har tippet Børsen om opjusteringen. De er lavt bemandet pga påsken.
-
-
Selv tak JKY. Du var først.
-
New: Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma NCT03477539 - https://clinicaltrials.gov/ct2/show/NCT03477539
-
sure, it's an important study. They now use MRDneg measuring in stead of PFS as primary outcome, which make the study-time much shorter. And secondly they make a "light" version out of the transplant setting. To see if dara alone as pre-treatment is enough, and if dara+len as maintemance is enough.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind